Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Non-Current Liabilities (2022 - 2024)

Historic Total Non-Current Liabilities for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2024 value amounting to $41.5 million.

  • NewAmsterdam Pharma's Total Non-Current Liabilities changed N/A to $41.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $41.5 million, marking a year-over-year change of. This contributed to the annual value of $50.9 million for FY2023, which is 33018.31% up from last year.
  • As of Q3 2024, NewAmsterdam Pharma's Total Non-Current Liabilities stood at $41.5 million.
  • Over the past 5 years, NewAmsterdam Pharma's Total Non-Current Liabilities peaked at $60.2 million during Q1 2024, and registered a low of $11.4 million during Q2 2023.
  • For the 3-year period, NewAmsterdam Pharma's Total Non-Current Liabilities averaged around $37.0 million, with its median value being $43.7 million (2024).
  • In the last 5 years, NewAmsterdam Pharma's Total Non-Current Liabilities soared by 33018.31% in 2023 and then soared by 30110.68% in 2024.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's Total Non-Current Liabilities stood at $11.8 million in 2022, then soared by 330.18% to $50.9 million in 2023, then fell by 18.45% to $41.5 million in 2024.
  • Its Total Non-Current Liabilities stands at $41.5 million for Q3 2024, versus $45.9 million for Q2 2024 and $60.2 million for Q1 2024.